BioNTech (NASDAQ:BNTX) CEO Sells $4,628,250.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 45,000 shares of BioNTech stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00. Following the completion of the sale, the chief executive officer directly owned 813,209 shares in the company, valued at $83,638,545.65. This trade represents a 5.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.

BioNTech Stock Performance

NASDAQ BNTX traded down $5.10 on Tuesday, hitting $98.66. 1,103,851 shares of the stock traded hands, compared to its average volume of 1,114,410. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The business’s fifty day moving average is $96.82 and its two-hundred day moving average is $95.61. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The firm has a market capitalization of $24.95 billion, a price-to-earnings ratio of -12.60 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.60) EPS. As a group, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC increased its stake in BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares in the last quarter. EFG International AG purchased a new position in BioNTech during the fourth quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd lifted its position in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares in the last quarter. Finally, Vestcor Inc acquired a new stake in shares of BioNTech during the fourth quarter worth $153,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BNTX. Berenberg Bank dropped their target price on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Citigroup decreased their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. Morgan Stanley cut their price objective on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Finally, Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.